San Francisco startup Composition Therapeutics can also be working on an oral, the moment-each day GLP-1 drug called GSBR-1290—the drug surpassed Wall Street’s expectations in June any time a mid-stage study confirmed average weight loss of around six% and it plans to get started on another mid-stage trial in direction of the tip of the 12 mont